JP2020514316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514316A5 JP2020514316A5 JP2019540532A JP2019540532A JP2020514316A5 JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5 JP 2019540532 A JP2019540532 A JP 2019540532A JP 2019540532 A JP2019540532 A JP 2019540532A JP 2020514316 A5 JP2020514316 A5 JP 2020514316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000011580 syndromic disease Diseases 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 150000003573 thiols Chemical class 0.000 claims description 16
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- DNISYQIZVIFCRA-UHFFFAOYSA-N 4-(1-aminoethyl)-2,6-ditert-butylphenol Chemical compound CC(N)C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 DNISYQIZVIFCRA-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000375 suspending agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129286A JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451285P | 2017-01-27 | 2017-01-27 | |
| US62/451,285 | 2017-01-27 | ||
| US201762454131P | 2017-02-03 | 2017-02-03 | |
| US62/454,131 | 2017-02-03 | ||
| PCT/IB2018/050497 WO2018138684A1 (en) | 2017-01-27 | 2018-01-26 | Cyclic dinucleotides as sting agonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Division JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514316A JP2020514316A (ja) | 2020-05-21 |
| JP2020514316A5 true JP2020514316A5 (enExample) | 2021-03-04 |
| JP7213188B2 JP7213188B2 (ja) | 2023-01-26 |
Family
ID=61187609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540532A Active JP7213188B2 (ja) | 2017-01-27 | 2018-01-26 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129286A Pending JP2022163188A (ja) | 2017-01-27 | 2022-08-15 | Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11021511B2 (enExample) |
| EP (1) | EP3573717B1 (enExample) |
| JP (2) | JP7213188B2 (enExample) |
| CN (1) | CN110234404A (enExample) |
| AU (1) | AU2018212787B2 (enExample) |
| ES (1) | ES2891326T3 (enExample) |
| WO (1) | WO2018138684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3429596B1 (en) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| WO2019043634A2 (en) | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS |
| MX2020004858A (es) | 2017-11-10 | 2020-10-01 | Takeda Pharmaceuticals Co | Compuestos moduladores de sting y metodos de elaboracion y uso. |
| US11161864B2 (en) | 2018-10-29 | 2021-11-02 | Venenum Biodesign, LLC | Sting agonists |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| WO2020106736A1 (en) * | 2018-11-19 | 2020-05-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| US11787833B2 (en) | 2019-05-09 | 2023-10-17 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| CA3145889A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| WO2021252904A1 (en) * | 2020-06-11 | 2021-12-16 | Massachusetts Institute Of Technology | Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| EP4240488A1 (en) | 2020-11-09 | 2023-09-13 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
| TW202317087A (zh) | 2021-08-10 | 2023-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關病況之化合物及組合物 |
| CN120757600B (zh) * | 2025-09-10 | 2025-11-11 | 天津法尔玛制药有限公司 | 环二核苷酸2′,3′-cG4′-MeAMP、制备方法及其在制备先天免疫激活剂中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| EP1368458A2 (en) | 2001-02-26 | 2003-12-10 | Pharma Pacific Pty. Ltd. | Interferon-alpha induced gene |
| WO2005005450A1 (ja) * | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | 環状ビスジヌクレオシドの合成方法 |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| SG10201708821RA (en) * | 2013-04-29 | 2017-12-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| ES2754269T3 (es) | 2013-05-18 | 2020-04-16 | Aduro Biotech Inc | Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| US20160287623A1 (en) | 2013-11-19 | 2016-10-06 | The University Of Chicago | Use of sting agonist as cancer treatment |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| EP3233089A4 (en) * | 2014-12-17 | 2018-11-14 | Lipogen LLC | Method of treating cancer with cgamp or cgasmp |
| GB201501462D0 (en) * | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| MA42608A (fr) * | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| CN108430503A (zh) | 2015-10-28 | 2018-08-21 | 艾杜罗生物科技公司 | 用于激活“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| CA3006930A1 (en) | 2015-12-03 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| EP3429596B1 (en) | 2016-03-18 | 2022-08-31 | Immune Sensor, LLC | Cyclic di-nucleotide compounds and methods of use |
| WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| WO2018009466A1 (en) * | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JOP20170188A1 (ar) * | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| US20200113924A1 (en) * | 2016-12-20 | 2020-04-16 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| AU2017378782A1 (en) * | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
-
2018
- 2018-01-26 US US16/478,864 patent/US11021511B2/en not_active Expired - Fee Related
- 2018-01-26 ES ES18703857T patent/ES2891326T3/es active Active
- 2018-01-26 CN CN201880009027.3A patent/CN110234404A/zh active Pending
- 2018-01-26 WO PCT/IB2018/050497 patent/WO2018138684A1/en not_active Ceased
- 2018-01-26 AU AU2018212787A patent/AU2018212787B2/en not_active Expired - Fee Related
- 2018-01-26 JP JP2019540532A patent/JP7213188B2/ja active Active
- 2018-01-26 EP EP18703857.5A patent/EP3573717B1/en active Active
-
2022
- 2022-08-15 JP JP2022129286A patent/JP2022163188A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514316A5 (enExample) | ||
| JP2020500862A5 (enExample) | ||
| JP2020505405A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2020507589A5 (enExample) | ||
| JP2013545730A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2017531619A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2009535352A5 (enExample) | ||
| JP2020505354A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| CA2682494A1 (en) | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders | |
| JP2019510027A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2018534288A5 (enExample) | ||
| JP2012520321A5 (enExample) | ||
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. |